Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company, is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy and vaccines. Its proprietary drug candidates act via unique mechanisms that are designed to kill cancer and protect healthy cells. Operationally, the company’s personnel combine proven scientific expertise and a depth of knowledge about their products’ mechanisms of action into a passion for developing drugs to save lives. For more information, visit the company’s website at www.cbiolabs.com.